Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Costs and Expenses:    
General and administrative $ 1,655,000 $ 1,419,000
Research and development 2,597,000 1,118,000
Total Operating Costs and Expenses 4,252,000 2,537,000
Loss from Operations (4,252,000) (2,537,000)
Other Expense:    
Exchange loss (23,000) 0
Interest income 2,000 0
Total Other Expense (21,000) 0
Net Loss (4,273,000) (2,537,000)
Net Loss Attributable to Non-controlling Interest 0 (1,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (4,273,000) (2,536,000)
Effect of Series A Preferred Stock Price adjustment 0 (7,402,000)
Net Loss Attributable to Common Stockholders $ (4,273,000) $ (11,459,000)
Net Loss Per Share - Basic $ (0.03) $ (0.13)
Net Loss Per Share - Dilutive $ (0.03) $ (0.13)
Weighted average number of shares outstanding during the period - basic 138,201,442 90,807,693
Weighted average number of shares outstanding during the period - dilutive 138,201,442 90,807,693
Series A Preferred Stock [Member]    
Other Expense:    
Preferred Stock Dividends, Income Statement Impact $ 0 $ (24,000)
Effect of Series A Preferred Stock Price adjustment 0 (7,402,000)
Series B Preferred Stock [Member]    
Other Expense:    
Net Loss Attributable to Non-controlling Interest   100,000
Preferred Stock Dividends, Income Statement Impact 0 (1,497,000)
Net Loss Attributable to Common Stockholders   (11,500,000)
Preferred Stock [Member] | Series B Preferred Stock [Member]    
Other Expense:    
Net Loss Attributable to Non-controlling Interest   0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ 0 $ 0